Literature DB >> 8702959

Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo.

T Okadome1, E Oeda, M Saitoh, H Ichijo, H L Moses, K Miyazono, M Kawabata.   

Abstract

The type I transforming growth factor-beta receptor (TbetaR-I) is the efferent component of the receptor complex, which presumably phosphorylates intracellular targets. FKBP12, a binding protein for FK506 and rapamycin, is shown to associate with the cytoplasmic region of TbetaR-I in vitro. In this report, we investigated the interaction of FKBP12 with TbetaR-I in vivo. FKBP12 interacts with TbetaR-I in mammalian cells as well as in yeast. Ligand addition does not affect the interaction, and both constitutively active and kinase-negative mutants of TbetaR-I bind FKBP12. FKBP12 dissociates from TbetaR-I in the presence of a high concentration of FK506. The juxtamembrane region of TbetaR-I, containing the major phosphorylation sites by the type II receptor, is required for the interaction. One of the deletion mutants in this region, which was shown to mediate transcriptional response, does not bind FKBP12, suggesting that FKBP12 is not directly involved in TGF-beta signaling. Furthermore TbetaR-I does not phosphorylate FKBP12 in vitro. FKBP12 may not be a direct substrate of TbetaR-I but possibly modulates the TbetaR-I function through its interaction with the regulatory domain of the kinase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702959     DOI: 10.1074/jbc.271.36.21687

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.

Authors:  Celia L Gregson; Peter Hollingworth; Martin Williams; Kirsten A Petrie; Alex N Bullock; Matthew A Brown; Jon H Tobias; James T Triffitt
Journal:  Bone       Date:  2010-10-29       Impact factor: 4.398

2.  A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity.

Authors:  X H Feng; R Derynck
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

3.  Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.

Authors:  Brian K Law; Anna Chytil; Nancy Dumont; Elizabeth G Hamilton; Mary E Waltner-Law; Mary E Aakre; Cassondra Covington; Harold L Moses
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

4.  Template-based docking of a prolactin receptor proline-rich motif octapeptide to FKBP12: implications for cytokine receptor signaling.

Authors:  K V Soman; B A Hanks; H Tien; M V Chari; K D O'Neal; J D Morrisett
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

5.  Mechanism of TGFbeta receptor inhibition by FKBP12.

Authors:  Y G Chen; F Liu; J Massague
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

6.  FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle.

Authors:  B Aghdasi; K Ye; A Resnick; A Huang; H C Ha; X Guo; T M Dawson; V L Dawson; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

7.  Variable signaling activity by FOP ACVR1 mutations.

Authors:  Julia Haupt; Meiqi Xu; Eileen M Shore
Journal:  Bone       Date:  2017-10-31       Impact factor: 4.398

Review 8.  Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.

Authors:  Jorge A Garcia; David Danielpour
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

9.  Rapamycin activates TGF receptor independently of its ligand: implications for endothelial dysfunction.

Authors:  Ayumi A Miyakawa; Thais Girão-Silva; Jose E Krieger; Elazer R Edelman
Journal:  Clin Sci (Lond)       Date:  2018-02-16       Impact factor: 6.124

10.  Pathogenic ACVR1R206H activation by Activin A-induced receptor clustering and autophosphorylation.

Authors:  Anassuya Ramachandran; Merima Mehić; Laabiah Wasim; Dessislava Malinova; Ilaria Gori; Beata K Blaszczyk; Diana M Carvalho; Eileen M Shore; Chris Jones; Marko Hyvönen; Pavel Tolar; Caroline S Hill
Journal:  EMBO J       Date:  2021-05-18       Impact factor: 14.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.